



ASX Release

22 January 2018

ZELDA THERAPEUTICS LIMITED
ACN 103 782 378

Level 45
108 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
W: www.zeldatherapeutics.com

Contacts

Corporate

Mr Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Investors

Dr Stewart Washer
Executive Director
+61 418 288 212
swasher@zeldatherapeutics.com

Directors

Mr Harry Karelis
Dr Stewart Washer
Ms Mara Gordon
Mr Jason Peterson

Tickers:

Australia (ASX): ZLD
USA (OTC): ZLDAF

Ordinary Shares:

755,341,934

Options:

46,000,000

1,500,000 (\$0.04 – 6/2/2020)

*4,500,000 (\$0.04 – 6/2/2020)

*40,000,000 (\$0.03125 – 17/11/2021)

* subject to vesting conditions

Shares Commence Trading in the USA on the OTCQB Venture Market

- **Zelda increases its international footprint by trading on the US public market**
- **USA-based investors now have easier investment access to Zelda's shares**
- **Underlines Zelda's commitment to maintaining a leading international position in the global medicinal cannabis sector**
- **Facilitates greater investor access to the Company's activities**
- **Significantly expands the pool of investors able to invest in the Company**

Zelda Therapeutics Limited (ASX: ZLD, OTCQB: ZLDAF, "the Company" or "Zelda") is pleased to announce that the Company's ordinary shares have been approved for trading on the OTCQB Venture Market (OTCQB) in the United States of America under the symbol "ZLDAF."

For clarity, this dual listing structure is non-dilutive to existing Zelda shareholders – that is, no capital is being raised and no new shares are being issued.

This listing provides a new source of demand for Zelda shares from the USA – the largest pool of investors in the world.

The OTCQB is a US-based trading platform operated by OTC Markets Group in New York. The OTCQB Venture Market is for early-stage and developing USA and international companies. To be eligible companies must:

- be current in their financial reporting;
- pass a minimum \$0.01 bid price test; and
- undergo an annual company verification and management certification process.

The OTCQB quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for USA-based investors.

Through trading on OTCQB, companies can engage a far greater network of US investor, data distributors and media partners, ensuring US investors have access to the same high-quality information that is available to investors in Australia, but through US platforms and portals used to conduct investment research.

The securities law firm Sichenzia Ross Ference Kesner LLP served as the Company's OTC Markets Sponsor and Viriathus Capital LLC served as the Company's financial advisor.

Harry Karelis, Chairman said: *“We are pleased to announce our new trading relationship with OTCQB. As part of our ongoing strategy to introduce Zelda Therapeutics to a broader international audience, this milestone will provide greater visibility, better access to the US investment community, and improved convenience of trading in Zelda’s ordinary shares. We expect to achieve a number of significant milestones over the course of 2018 that we believe will be of great interest to US-based investors and this listing forms part of an overall investor relations strategy.”*

Tim Slate
Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics (“Zelda”) is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A human clinical trial programme focused on insomnia, autism and eczema with activities in Australia, Chile and the United States.
- A pre-clinical research programme examining the effect of cannabinoids in breast, brain and pancreatic cancer. It has partnered with the world’s leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.